Utilizing prognostic and predictive factors in breast cancer.

作者: Deepa S. Subramaniam , Claudine Isaacs

DOI: 10.1007/S11864-005-0022-1

关键词:

摘要: In order to make optimal treatment recommendations for patients with early-stage breast cancer, it is essential accurately determine the patient’s underlying risk of disease recurrence and choose a therapy which individual most likely respond. Lymph node status, tumor size, histopathologic features including type grade, hormone receptor status are well-accepted prognostic factors related cancer. addition, very strong predictor response hormonal therapy. However, our currently accepted predictive fall short there critical need more identify those require or benefit from particular therapies. Attention has therefore focused on determination novel factors. The promising new factor level urokinase plasminogen activator its inhibitor inhibitor. Other putative include proliferative rate, presence lymphatic vascular invasion, human epidermal growth 2 (HER-2/neu erbB-2) positivity, micrometastases in lymph nodes bone marrow, gene expression profile by microarray analysis, RNA-based methodology. Data regarding potential constantly emerging. These studies frequently challenging interpret as they often retrospective, based relatively small numbers patients, mix treated untreated women, do not control other known Therefore, data must be interpreted caution.

参考文章(56)
Tanja Fehm, Elisabeth Merkle, Wolfram Jaeger, Margarete Mitze, Gerhard Gebauer, Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years. Anticancer Research. ,vol. 23, pp. 4319- 4324 ,(2003)
Aron Goldhirsch, John H. Glick, Richard D. Gelber, Alan S. Coates, Hans-Jörg Senn, Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. Journal of Clinical Oncology. ,vol. 19, pp. 3817- 3827 ,(2001) , 10.1200/JCO.2001.19.18.3817
M F Press, L Bernstein, P A Thomas, L F Meisner, J Y Zhou, Y Ma, G Hung, R A Robinson, C Harris, A El-Naggar, D J Slamon, R N Phillips, J S Ross, S R Wolman, K J Flom, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology. ,vol. 15, pp. 2894- 2904 ,(1997) , 10.1200/JCO.1997.15.8.2894
Sami G. Diab, Gary M. Clark, C. Kent Osborne, Arlene Libby, D. Craig Allred, Richard M. Elledge, Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. Journal of Clinical Oncology. ,vol. 17, pp. 1442- 1448 ,(1999) , 10.1200/JCO.1999.17.5.1442
Sylvie Ménard, Pinuccia Valagussa, Silvana Pilotti, Luca Gianni, Elia Biganzoli, Patrizia Boracchi, Gorana Tomasic, Patrizia Casalini, Ettore Marubini, Maria I. Colnaghi, Natale Cascinelli, Gianni Bonadonna, Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables Journal of Clinical Oncology. ,vol. 19, pp. 329- 335 ,(2001) , 10.1200/JCO.2001.19.2.329
Hideko Yamauchi, Vered Stearns, Daniel F. Hayes, When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer Journal of Clinical Oncology. ,vol. 19, pp. 2334- 2356 ,(2001) , 10.1200/JCO.2001.19.8.2334